Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!
Members of the NAAF team represented the organization and the alopecia areata patient community at the 2024 Annual Meeting of…
Key leaders of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) met with NAAF President & CEO,…
Applications for Student Internship Awards for 2024 are now open. These awards support students (undergraduate, graduate, or medical), residents, or…
Media reports of two newly approved drugs for treating alopecia areata brought good news to many people living with the…
NAAF is pleased to announce that Zura Bio has joined the Industry Partner Program at the Bronze membership level. Zura…
Today, the U.S. Food and Drug Administration (FDA) approved LITFULO™ for severe alopecia areata, marking the second FDA-approved treatment for…
Does alopecia areata (AA) affect all races and ethnic groups equally? If yes, why is this important? Knowing AA prevalence…
Results from a clinical trial for a new treatment for alopecia areata were published in the medical journal The Lancet…
As we come to the close of 2022, we look upon these past 12 months as among the most pivotal…
When you participate in a survey that comes to you in a NAAF email, what happens to your responses? For…
